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C1q acts in the tumour microenvironment as a
cancer-promoting factor independently of
complement activation
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Complement C1q is the activator of the classical pathway. However, it is now recognized that
C1q can exert functions unrelated to complement activation. Here we show that C1q, but not
C4, is expressed in the stroma and vascular endothelium of several human malignant
tumours. Compared with wild-type (WT) or C3- or C5-deﬁcient mice, C1q-deﬁcient
(C1qa / ) mice bearing a syngeneic B16 melanoma exhibit a slower tumour growth and
prolonged survival. This effect is not attributable to differences in the tumour-inﬁltrating
immune cells. Tumours developing in WT mice display early deposition of C1q, higher
vascular density and an increase in the number of lung metastases compared with C1qa /
mice. Bone marrow (BM) chimeras between C1qa / and WTmice identify non-BM-derived
cells as the main local source of C1q that can promote cancer cell adhesion, migration and
proliferation. Together these ﬁndings support a role for locally synthesized C1q in promoting
tumour growth.
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C
ells undergoing malignant transformation acquire the
ability to proliferate in an uncontrolled manner invading
the surrounding tissue and spreading to distant organs via
the circulatory or lymphatic systems1. There is strong evidence
that tumour growth not only depends on the accumulation of
genetic abnormalities in the originating cancer cells, but also on
the local microenvironment that can provide a permissive niche
for the survival, growth and migration of the cancer cells2,3.
Tumour cells recognized by the immune system are kept under
surveillance by the combined action of the innate and adaptive
immune systems and are either eliminated or remain quiescent
for long time4,5. The latter situation is difﬁcult to detect in vivo
due to the absence of clinical symptoms, but its existence is
supported by the ﬁndings of dormant tumours at autopsy of
patients deceased for other reasons6–8. Conversely, fast growing
cancer cells develop strategies to escape immune defences5,9–11.
They can trigger local inﬂammation that promotes disease
progression rather than controlling tumour growth12–14. This
process is characterized by the peri-tumoral recruitment of
leucocytes with immunosuppressive properties such as tumour-
associated macrophages, myeloid-derived suppressor cells
(MDSCs) and regulatory T cells15.
The complement (C) system, a well-known arm of innate
immunity16,17, is one of the immune players present in the
tumour microenvironment as suggested by the ﬁnding of C
deposits on tumour tissue from patients with breast, papillary
thyroid, colorectal and ovarian carcinoma18–20. The involvement
of C in cancer immunosurveillance has long been neglected until
monoclonal antibodies (mAbs) to tumour-associated antigens
were introduced in cancer therapy21. In addition to mediating
antibody-dependent cell cytotoxicity (ADCC), some mAbs can
trigger C activation that helps control tumour growth by a
direct cytotoxic effect on cancer cells and/or by promoting
inﬂammation22–25. The advantage of the C system over ADCC is
that it is made of soluble components readily available at tissue
sites where they are secreted by local and recruited cells and
sometimes by the same tumour cells. However, the contribution
of C to the killing of cancer cells remains unclear because tumour
cells overexpress membrane-bound C regulatory molecules
(CRPs) such as CD46, CD55 and CD59 (refs 24,26,27) that can
limit the cytotoxic effects of C activation. The importance of
CRPs in tumour protection has been highlighted by a recent
study showing that bispeciﬁc antibodies containing C-ﬁxing
anti-CD20 mAb and neutralizing Abs to CRPs are highly
effective in vivo in cancer immunosurveillance28. Furthermore,
data accumulated over the last few years suggest a tumour-
promoting role for the C system29. Markiewski et al.30 ﬁrst
reported that C5a, generated in the tumour microenvironment as
a result of C activation, favours cervical cancer growth by
recruiting and activating MDSCs. This observation together with
similar ﬁndings in mouse models of lung and ovarian
cancers31,32, and more recently of mesenchymal and epithelial
carcinogenesis33, challenges the concept that C activation at
tumour site is always beneﬁcial for cancer patients. However, the
clinical relevance of these ﬁndings in animal models remains to
be established especially as C5a has also been found to control
tumour growth34,35 and to exert opposite effects depending on
the amount available in the tumour microenvironment36.
Irrespective of the beneﬁcial or harmful impact of C on tumour
growth, all the C-mediated effects have been found to be
associated with fragments such as C3a and C5a implying C
activation37,38.
Here we present data showing that the ﬁrst component of the C
system, C1q, can act as tumour-promoting factor by favouring
adhesion, migration and proliferation of cancer cells as well as
angiogenesis and metastasis. C1q is synthesized in the tumour
microenvironment and acts like a protein of the extracellular
matrix favouring tumour growth and metastasis. These ﬁndings
demonstrate that C1q can contribute to tumour progression and
invasion regardless of C activation.
Results
C1q is expressed in the microenvironment of human cancers.
We have recently reported that C1q favours trophoblast invasion
of maternal decidua39 and promotes angiogenesis in wound
healing40. As these features are shared to some degree by growing
tumours, the possibility that C1q may contribute to this process
was raised. We initially searched for the presence of C1q, C1s, C4
and C3 in a panel of 30 invasive malignant neoplasm specimens
including 6 cases of colon adenocarcinoma, 6 cases of melanoma,
6 cases of lung adenocarcinoma, 6 cases of breast
adenocarcinoma and 6 cases of pancreatic adenocarcinoma. As
shown in Fig. 1, a strong signal for C1q was detected in all
tumour specimens examined, while other C components were
either absent (C4) or mildly expressed (C1s and C3) suggesting
that C1q deposition did not result in the activation of the classical
pathway. Within the tumour microenvironment, C1q was mainly
expressed by mesenchymal elements including vascular
endothelial cells and spindle-shaped ﬁbroblasts (arrows) and
monocytoid cells suggestive of tumour-inﬁltrating myeloid
elements (arrow heads) (Fig. 1b). C1q expression within newly
formed tumour-associated vascular endothelia was further
conﬁrmed by double-staining with CD34, an endothelial
marker (Fig. 2a). Similarly, the C1q expression in mesenchymal
and immune cells was corroborated by double-staining
immunoﬂuorescence analyses of invasive colon and breast
cancer specimens using markers speciﬁc for epithelial
(pan-cytokeratin), mesenchymal (vimentin) or immune cells
(CD45) (Supplementary Fig. 1). In agreement with the
immunohistochemical analyses, malignant cells, identiﬁed by
cytokeratin immunostaining (Supplementary Fig. 1, left panels,
green signal), did not show C1q expression (red signal). By
contrast, mesenchymal elements, detected using vimentin as a
marker (middle panels, green signal), diffusely expressed C1q
(red signal). Immune cells positive for CD45 (right panels,
green signal) also expressed C1q (red signal), though this was not
visible in all inﬁltrating cells. Notably, C1q expression in the
mesenchymal elements appeared to be associated with cancer
invasion since C1q was clearly detected in stromal elements at the
tumour invasion edge (Fig. 2b), but not in the tumour cells
(Supplementary Fig. 2). Consistent with this, C1q was not
detected in non-transformed and non-inﬁltrated peri-tumoral
tissues (Fig. 2d). Moreover, the association between C1q
expression and tumour stroma was not conﬁned to primary
lesions as it was also observed in the stroma of metastatic tumour
foci (Fig. 2c). Overall, these in situ analyses conﬁrmed that C1q
expression within the tumour microenvironment is mainly
limited to the stromal elements suggesting its relevance in
cancer cell-extrinsic dynamics.
Prolonged survival and reduced tumour mass in C1qa / mice.
The presence in tumour tissues of C1q in the absence of other
components of the classical C pathway led us to evaluate the
contribution of this molecule to tumour growth in a syngeneic
model of melanoma developed in C57BL/6 WT mice. After pilot
experiments to deﬁne the optimal experimental conditions for
inducing tumour growth and lung metastasis in a high proportion
of mice, we selected the model in which 2 106 B16/F10
melanoma cells are injected intramuscularly. In WT animals, the
tumour mass reached a mean of 6 cm3 20 days after the cell
injection (Fig. 3a) and the mice were all humanely culled by 32
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days (Fig. 3b). In contrast, C1qa / mice exhibited a prolonged
survival with signiﬁcantly slower tumour growth throughout the
period of observation, while the tumour growth and the survival
rates of both C3- and C5-deﬁcient animals did not differ from
those of WT animals (Fig. 3a,b). A marked difference in the
tumour growth rate between C1qa / and WT mice was also
observed using the syngeneic mouse model of lung carcinoma
(Supplementary Fig. 3). Consistent with the ﬁndings in human
specimens, immunohistochemical analysis of the tumour masses
showed marked deposition of C1q on vascular endothelium and
stroma in the absence of C4. The C3 staining was scattered and
mainly associated with tumour-inﬁltrating cells (Fig. 3c). To
characterize better the cellular source of C1q and C3, the tumour
sections were also stained with an antibody against CD68, a
widely used marker for tissue macrophages. As shown in Fig. 3d,
C3 was expressed almost exclusively in CD68þ cells, while C1q
staining was present in both CD68þ and CD68 cells, the latter
most likely representing stromal cells. Moreover, kinetic analysis
of C expression in the growing tumour revealed the presence of
C1q as early as 2 days after tumour cell injection preceding the
expression of C3 that was detectable only 2 days later and became
obvious on day 6 (Supplementary Fig. 4a). Further analysis of C3
expression using an antibody that recognizes only C3 activation
products failed to detect cleaved C3 fragments within the tumour
sections (Supplementary Fig. 4b).
In subsequent experiments, we killed the animals at day 12 and
analysed by ﬂow cytometry the tumour-inﬁltrating immune
cells. Although the tumour sizes were markedly different
(Supplementary Fig. 5), the percentages and phenotype of
CD4þ and CD8þT cells within the tumour mass were similar
(Supplementary Fig. 6). In addition, we failed to detect a higher
frequency or an increased suppressive ability of the myeloid-
derived suppressor cells in WT mice that could explain the
enhanced tumour growth in these animals compared with the
C1qa / mice (Supplementary Fig. 7a–c).
Tumour growth in BM transplanted mice. To determine the
contribution of stromal-derived C1q to the development of the
tumour, we generated reciprocal radiation bone marrow (BM)
chimeras between C1qa / and WT mice. In agreement with
our previous ﬁndings41,42, 2 months after the BM transplant, C1q
levels in the C1q-deﬁcient recipients were almost comparable to
those in control WT chimeras (Fig. 4a). In contrast, the C1q levels
in WT mice reconstituted with C1qa / BM cells were hardly
detectable. The development of the tumour in the BM chimeras
was then evaluated (Fig. 4b). A progressive increase in tumour
was observed in all experimental groups during the period of
observation. However, at each time point this increase was
markedly less pronounced in the C1qa / irradiated recipient
mice regardless of the circulating C1q levels. Syngeneic
reconstituted C1qa / mice and chimeric mice becoming C1q
sufﬁcient after BM transplantation developed smaller tumours.
Conversely, WT mice reconstituted with C1qa / BM cells and
syngeneic reconstituted WT mice showed accelerated tumour
growth (Fig. 4b). Taken together these data indicate that the
non-BM-derived C1q was a critical factor for the tumour growth.
The cellular source of C1q was then analysed by immuno-
ﬂuorescence using antibodies against C1q (red) and CD68 to
identify macrophages (green) (Fig. 4c). As expected, C1q was
undetectable in C1qa / mice reconstituted with C1qa / BM
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Figure 1 | Immunohistochemical analysis of classical C components in human tumours. (a) Representative microphotographs showing the expression of
C1q, C1s, C4 and C3 in different malignant cancer histotypes. Streptavidin–biotin–peroxidase complex system with AEC (red) chromogen; scale bars,
100mm. (b) C1q expression in tumour-associated stroma of different cancer histotypes. Highlighted are monocytoid cells suggestive of tumour-inﬁltrating
myeloid elements (arrow heads) and mesenchymal elements including vascular endothelial cells and spindle-shaped ﬁbroblasts (arrows).
Streptavidin–biotin–peroxidase complex system with AEC (red) chromogen; scale bars, 50mm.
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cells, while it was present in endothelial cells and in CD68þ cells
in WT mice receiving WT BM cells. Vascular endothelium and
CD68 non-BM-derived cells expressed C1q in WT mice
reconstituted with C1qa / BM cells. Conversely, endothelial
cells did not stain for C1q in C1qa / recipients of WT BM cells
that colonize the tumour mass with macrophages expressing C1q.
Effects of C1q on tumour angiogenesis and metastases. As
cancer development largely depends on angiogenesis43–45, we
then examined the degree of new vessel formation in the tumour
tissue. We found that the vascular density in tumour-bearing
WT mice was signiﬁcantly higher than in C1qa / animals,
particularly in the peri-tumoral area (Fig. 5a–d). We also searched
for metastatic melanoma cells in the lungs, the organ
preferentially colonized by the cancer cells that escape from the
primary tumour site, and detected metastases in 6 out of 11 WT
mice but only in 1 out of 11 C1qa / mice (Fig. 5e–f).
Biological effects of C1q on murine melanoma cells. Having
established that C1q is present in the tumour mass, we sought to
investigate the mechanism(s) by which C1q contributed to
tumour growth by analysing its ability to promote adhesion,
proliferation and migration of cancer cells. To evaluate the
C1q-mediated effects, melanoma cells were labelled with the
ﬂuorescent probe FAST DiI (Molecular Probes, Invitrogen) and
allowed to adhere to plate-bound C1q or a mixture of ﬁbronectin
(FN) and C1q, using bovine serum albumin (BSA) and FN as
negative and positive controls, respectively. C1q was able to
promote the adhesion of 33% of cells as opposed to nearly 13% of
cells adhering to BSA. In addition, it enhanced the pro-adhesive
activity of FN to B80% following its interaction with this
extracellular matrix protein (Fig. 6a). A high fraction of cells
bound to FN appeared spread out and displayed actin-containing
stress ﬁbres, in contrast with the round morphology exhibited by
the great majority of those attached to C1q and by a proportion of
cells adhering to C1q bound to FN (Fig. 6c). The ability of C1q to
induce cell migration was examined by adding the tumour cells
to the upper chamber of a transwell system and allowing them to
migrate through an insert coated with C1q or FN or both. C1q
was slightly more effective than FN, allowing migration of 87% of
cells that increased to 96% with the mixture of C1q and FN
(Fig. 6b).
Given the in vivo ﬁndings that C1q promotes cancer
progression, we then explored whether C1q might contribute to
tumour growth by stimulating the proliferation of cancer cells.
To this end, the melanoma cells were incubated with either plate-
bound C1q or FN or the mixture of both and the number of
proliferating cells was counted with the Coulter Particle Counter.
As shown in Fig. 6d, C1q induced cell proliferation comparable to
that obtained with FN and the total number of proliferating cells
increased further after stimulation with both. In addition, cells
adhering to C1q, unlike those bound to FN, were protected from
apoptosis induced by oxidative stress (Fig. 6e). Moreover, a
reduced frequency of proliferating tumour cells was also detected
in the C1q-deﬁcient mice in vivo using BrdU incorporation
(Supplementary Fig. 7d).
Discussion
During cancer development, the tumour microenvironment with
inﬁltrating immune and non-immune cells, as well as the
extracellular matrix undergoes substantial changes that can
inﬂuence tumour progression46,47. The data presented in this
study demonstrate that C1q contributes to these changes
independently of C activation by acting as an external
component of the extracellular matrix and favouring tumour
growth and invasion.
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Figure 2 | Immunohistochemical analysis of primary and metastatic colon carcinoma for deposition of C1q. (a) Expression of C1q on vascular
endothelia demonstrated by double-marker immunohistochemical analysis showing co-localization of C1q (blue signal) and CD34 (red signal) in
vessels; scale bars, 50mm. (b) C1q expression in stromal tissue neighbouring neoplastic glandular foci at the edge of tumour inﬁltration in colon
adenocarcinoma (arrows); scale bars, 100mm. (c) C1q expression in the tumour-associated stroma at sites of liver metastasis of colon adenocarcinoma.
Streptavidin–biotin–peroxidase complex system with AEC (red) chromogen; scale bars, 100 mm. (d) Representative microphotographs showing differential
C1q expression in the stroma of cancer-involved and non-involved mucosa at lower magniﬁcation (left panel, scale bar, 200mm) and higher magniﬁcation
(middle and right panels, scale bars, 50mm). C1q-expressing, tumour-inﬁltrating myeloid elements (arrow heads) and mesenchymal elements including
vascular endothelial cells and spindle-shaped ﬁbroblasts (arrows) are differently enriched in the two conditions. Streptavidin–biotin–peroxidase complex
system with AEC (red) chromogen.
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Deposits of C components have been reported in different
human tumours and have been interpreted as the result of
C activation induced by several triggers including antibodies
to tumour-associated antigens, immune complexes and cell
damaged by necrosis and apoptosis18,19. The extent of C
activation, that in some cases proceeds up to the assembly of
the terminal complex48, depends on the tumour type and the
degree of inﬂammation associated with tumour invasion. We
found that C1q was the predominant C component deposited in
all the tumours examined in this study. Its localization on
endothelial cells and stroma is reminiscent of its distribution in
human decidua, where it is locally synthesized and secreted by
several cells including endothelial cells and trophoblasts39,49.
Although C1q deposition is usually regarded as an indication of
classical pathway activation, our failure to detect C4 makes this
unlikely and rather suggested an alternative mechanism for the
C1q involvement at tumour site, not necessarily related to
classical pathway activation. However, we cannot exclude
complement activation through the alternative pathway as
suggested by the weak C3 staining observed with an antibody
against human C3d.
Data accumulated in recent years have revealed non-canonical
functions exerted by C1q on cells of both innate and adaptive
immunity50–53 as well as on specialized cells localized in tissues
such as trophoblasts in placental decidua and microglial cells in
the central nervous system39,54. C1q levels have been reported to
be higher in aging brain and to contribute to age-related cognitive
decline55. In pregnancy C1q has been implicated in tissue
remodelling in maternal decidua required for successful embryo
implantation56. In this report, we describe for the ﬁrst time a
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Figure 3 | Effect of C1q on tumour growth and survival and analysis of tumour tissue for C deposition. WT (n¼ 14), C1qa / (n¼ 7), C3 / (n¼ 11)
and C5 / (n¼ 10) mice received an intramuscular injection of 2 106 B16/F10 melanoma cells and the tumour size (a) and survival (b) was monitored
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critical role for C1q in tumour development. Compared with WT
mice, C1q-deﬁcient mice bearing a syngeneic B16/F10 melanoma
had a markedly slower tumour growth with increased survival.
Failure to detect signiﬁcant differences in tumour growth and
survival between C3 / and WT mice ruled out the possibility
that the cancer-promoting effect of C1q was dependent on C
activation. This conclusion was further supported by the analysis
of the tumour mass in WT mice that revealed marked deposition
of C1q on vascular endothelium and stroma in the absence of C4,
while staining for C3 was almost exclusively restricted to CD68þ
cells and was nearly undetectable when using an antibody
detecting C3 activation fragments. C5-deﬁcient mice were also
included in our study as a control group because previous reports
have shown that C5a, generated through local C activation,
promotes tumour growth by recruiting MDSCs that can inhibit
T-cell-mediated anti-tumour responses30,57. The ﬁnding that the
melanoma cells grew in C5 / mice in a manner similar to that
observed in C3 / and WT mice ruled out the contribution of C
activation products, and more speciﬁcally of C5a, to tumour
progression under our experimental conditions. Furthermore, a
potential effect of C1q on the anti-tumour immune response was
excluded by the analysis of the peri-tumoral cell inﬁltrates that
revealed no differences in the percentage or phenotype of effector
T cells, macrophages and MDSCs between C1qa / and WT
mice. None of the immunological parameters analysed showed a
statistical signiﬁcant difference between the two experimental
groups. Together the ex vivo and in vivo data pointed to a direct
contribution of C1q to tumour growth independent of C
activation and raised the question of whether locally produced
C1q was responsible for its cancer-promoting effect.
It is well-known that BM-derived cells are the main source of
circulating C1q41. However, several other cell types can also
synthesize C1q and their contribution to the C1q-mediated
tumour-promoting effect was studied in BM transplanted mice.
Surprisingly, BM cells from WT mice, despite their ability to
reconstitute serum C1q levels in C1qa / animals had only a
negligible effect on tumour growth in these mice suggesting that
non-BM-derived cells were the relevant source of C1q needed for
its tumour-promoting activity. Included in this group of cells, in
addition to stromal cells, are endothelial cells that displayed
strong C1q staining in tumour developed in WT mice. Serum was
an unlikely source for the C1q bound to endothelial cells because
tumour endothelial cells from WT mice reconstituted with
C1q-deﬁcient BM cells still expressed C1q despite its nearly
undetectable level in circulation. A potential explanation for the
C1q expression on the surface of endothelial cells is that these
cells synthesize and secrete C1q in response to developing
tumour. Although we did not speciﬁcally address this point, there
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is evidence from our previous studies that endothelial cells may
acquire the ability to produce C1q at some tissue sites and in
certain pathophysiologic conditions like decidual endothelial cells
in pregnancy49 and dermal microvascular endothelial cells in
wound healing40. Consistent with this notion we found an
increased number of vessels both within the tumour mass and in
the peri-tumoral area. This ﬁnding extends to tumour, our
previous observations that C1q exhibits a pro-angiogenic activity
in wound healing40. As melanoma is considered a highly
angiogenic tumour that exploits newly formed vessels to receive
oxygen and nutrients and to establish metastasis58,59, it was not
surprising to see larger metastatic areas in tumour-bearing WT
mice compared with C1qa / mice. Tumour cells need to
proliferate to expand and C1q was also able to promote the
growth of the melanoma cells in vitro. Furthermore, as already
seen with trophoblasts39, melanoma cells bound to C1q appeared
to maintain a round morphology and this facilitates their
movement towards surrounding stromal areas and the
subsequent dissemination. Therefore our ﬁndings suggest that,
by interacting with proteins of the extracellular matrix like FN,
C1q offers an anchor to tumour cells for their initial seeding. The
pro-adhesive effect of C1q does not seem to be restricted to the
primary tumour, but can also be seen at metastatic sites as
suggested by its presence at lung metastases of colon carcinoma.
Among the different C1q receptors/binding molecules reported in
the literature, the receptor for the globular portion of C1q
(gC1qR), which was previously found to be expressed on
trophoblasts and to be capable of mediating C1q-induced cell
adhesion and migration39, was considered the most likely
candidate. Unfortunately, staining of the murine B16/F10
melanoma cells with the mAb 60.11 against human gC1qR, that
has been used to visualize the receptor on human cancer cells60,
failed to detect any gC1qR expression. The negative staining
could be due to a poor cross-reactivity of the antibody on murine
cells, but we cannot exclude that other molecule(s) may be
involved. Further investigations will be required to deﬁne the
underlying mechanisms of the C1q-mediated effects.
In conclusion, evidence collected from human tumours
revealed a persistent presence of C1q, mainly localized in the
stroma and on vascular endothelium, in the absence of C4.
Consistent with this, in a syngeneic melanoma model the lack of
C1q, but not of C3 or C4, reduced the tumour growth and
invasion. This tumour-promoting C1q-mediated effect was found
to be independent of the circulating C1q levels indicating
that non-BM-derived C1q might help tumour progression by
facilitating cancer cell seeding and promoting angiogenesis. Our
ﬁnding that C1q produced in the tumour microenvironment
favours cancer development is supported by a recent observation
by Winslow et al.61 that the genes for C1q A-, B- and C-chains
were highly expressed in the stroma of breast cancers with poor
prognosis.
Methods
Human tissues. Tumour tissue samples were obtained from the archives of the
Department of Human Pathology, University of Palermo, Italy. Thirty invasive
malignant neoplasm specimens were selected including six cases of colon
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Figure 5 | Angiogenesis and lung metastases in tumour-bearing mice. Quantiﬁcation of intra-tumoral (a) and peri-tumoral (c) MVD on 10 different
microscopic ﬁelds of tumour sections from 6 WT and 6 C1q-deﬁcient mice immunostained for CD31. Pooled data from two independent experiments.
Representative pictures of CD31-immunostained sections of tumour tissue from WT and C1q-deﬁcient mice showing intra-tumoral (b) and peri-tumoral
(d) CD31þ cells (arrows). Each symbol represents the number of vessels counted in one microscopic ﬁeld (10 ﬁelds per mouse, scale bars, 100mm) in 6
WT (ﬁlled square) and 6 C1qa / (ﬁlled triangles) mice. Horizontal lines indicate median. *Po0.05, **Po0.01 (Mann–Whitney U-test). (e) Measurement
of metastatic areas in the lungs of tumour-bearing WT (n¼ 11) and C1q-deﬁcient mice (n¼ 11). Each symbol represents the lung metastatic area (mm2) in
each WT (ﬁlled squares) and C1qa / (ﬁlled triangles) mice. Pooled data from two independent experiments. Horizontal lines indicate median, *Po0.05
(Mann–Whitney U-test). Representative images showing metastases in both groups of mice (f). Scale bars, 100 mm.
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adenocarcinoma, six cases of melanoma, six cases of lung adenocarcinoma, six
cases of breast adenocarcinoma and six cases of pancreatic adenocarcinoma. The
study was approved by the Institutional review board of the University of Palermo.
A speciﬁc informed consent was not requested at the time of tissue sample
collection for the immunohistochemical analysis of archival tissue sections pro-
vided that the patients were not identiﬁed and genetic analysis was not performed.
Mice. C57BL/6 WT mice were purchased from Harlan Laboratories. Mice deﬁcient
in C components C1q, C3 or C5 (respectively C1qa / , C3 / and C5 / )
were generated as described previously62–64. All strains were backcrossed onto the
C57BL/6 (B6) genetic background for more than 10 generations. All animals were
handled in accordance with the institutional guidelines and in compliance with the
European (86/609/EEC) and the Italian (D.L.116/92) laws. The Institutional
Animal Care Committee of the University of Trieste and the UK Home Ofﬁce
approved the procedures.
In vivo tumour models. B16/F10 melanoma (CRL-6475) and Lewis lung
carcinoma (LLC-1, CRL-1642) cell lines were purchased from the American Tissue
Culture Collection (Manassas,VA) and conﬁrmed to be mycoplasma free. The cells
were maintained in Minimum Essential Medium (Euroclone) supplemented with
10% (v/v) foetal bovine serum, 1% (v/v) penicillin–streptomycin solution, 2mM
L-glutamine, 100 mM non-essential amino acids, 1mM sodium pyruvate and
10mM HEPES (all from Life Technologies, Paisley, UK) in a humidiﬁed 5%
CO2 atmosphere at 37 C. C57BL/6 WT, C57BL/6.C1qa / , C57BL/6.C3 / or
C57BL/6.C5 / were injected intramuscularly into the left ﬂank of the mice with
viable B16/F10 cells (2 106) and tumour development was monitored daily. Both
male and female mice (8–12 weeks of age) were used. In each experiment the mice
were sex- and age-matched. Tumour size was measured every other day for the ﬁrst
week and then daily with calliper by determining two orthogonal axis, and the
volume was calculated using the following formula: (p/6)a2b, with a the shorter
and b the longer axis65. Measurements were performed by a blinded researcher.
According to our protocol (D.L.116/92), mice were culled before they developed
any signs of distress. When the animals were killed, tumours, spleens and lungs
were collected for analyses.
BM transplantation and assessment of C1q levels. Eight-week-old female mice
were irradiated at 8Gy using a 137Cs g-ray source and reconstituted with 107 BM
cells from sex-matched WT or C1qa / donors. Mice were kept under sterile
conditions for the ﬁrst 2 months after BMT. The successful reconstitution of the
haematopoietic lineages after BMT was monitored by ﬂow cytometry and by
measuring C1q levels in serum. Two months after the BMT mice were injected
intramuscularly with 2 106 viable B16/F10 cells and tumour growth monitored
up to day 14. Serum C1q levels were measured by ELISA as previously
described41,42. Brieﬂy, microtitre plates were coated with 1 mgml 1 of anti-mouse
C1q Ab (clone Rm C7H8; Connex) and blocked with 5% milk in PBS. Serum
samples were diluted appropriately in PBS–2%, BSA–0.05% and Tween 20–0.02%
NaN3. Bound C1q was detected with a biotinylated goat anti-mouse C1q antibody
(provided by F. Petry, Mainz, Germany, 1:10,000 dilution) followed by a
streptavidin–alkaline phosphatase conjugate (BD Bioscience, San Diego, 1:5,000
dilution) and revealed with p-nitrophenyl phosphate alkaline phosphates substrate
(Sigma-Aldrich). Optical density (OD) was measured at 405 nm. The results
were expressed in mgml 1, referring to a standard curve derived from a known
concentration of puriﬁed human C1q. C1q-deﬁcient mouse serum was included as
a negative control.
Immunohistochemical analysis. Immunohistochemistry was performed using a
polymer detection method. Tissue samples were ﬁxed in 10% buffered formalin
and parafﬁn embedded.
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Figure 6 | Effects of C1q on B16/F10 melanoma cell biology. Cell adhesion (a), migration (b), proliferation (d) and apoptosis (e) were performed as
detailed in Methods section. Data from at least ﬁve independent experiments are presented as mean±s.e.m., *Po0.05, **Po0.01, ***Po0.005 (one-way
ANOVA, Bonferroni corrections). (c) Representative images of tumour cells after incubation with C1q, FN and FNþC1q for 30min. Cells were stained
with NBD-phallacidin (green, dilution 1:50) and mouse monoclonal anti-paxillin Ab (dilution 1:100) followed by Cy3-conjugated goat anti-mouse IgG
(red, dilution 1:300) and analysed by confocal microscopy. Scale bars, 23 mm. f.u., ﬂuorescence units.
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Four-micrometer-thick tissue sections were deparafﬁnized and rehydrated. The
antigen unmasking technique was performed using Novocastra Epitope Retrieval
Solutions pH 6, pH 9 and pH 8 in a PT Link Dako pre-treatment module at 98 C
for 30min. The sections were then brought to room temperature and washed in
PBS. After neutralization of the endogenous peroxidase with 3% H2O2 and Fc
blocking by a speciﬁc protein block (Novocastra, UK), the samples were incubated
overnight at þ 4 C with the primary antibodies including rabbit polyclonal
anti-human C1q (Dako, Code A0136, 1/500 dilution), goat polyclonal anti-human
C1s (Quidel, Catalogue number A302, 1/100 dilution), rabbit polyclonal
anti-human C3d (Catalogue number 403A-76, 1/100 dilution) and anti-human
C4d (Catalogue number 404A-16, 1/100 dilution) both from Cell Marque
Sigma-Aldrich, mouse monoclonal anti-human CD31 (PECAM-1) (clone 1 A10,
1/50 dilution) and anti-human CD34 (clone QBEnd/10, 1/100 dilution) both from
Leica Biosystems (Newcastle, UK). IgG from normal mouse, rabbit and goat
sera were used as negative controls. Staining was revealed by the horseradish
peroxidase (HRP) polymer detection kit (Novocastra, Code RE7280-K) and AEC
(3-amino-9-ethylcarbazole) substrate-chromogen. Primary antibodies made in goat
were detected with HRP-conjugated rabbit anti-goat IgG Fc (Life Technologies
Corporation, Catalogue number A16148, 1/500 dilution) after incubation for 1 h at
room temperature. The sections were counterstained with Harris haematoxylin
(Novocastra) and analysed under a Leica DMD108 optical digital microscope
(Leica Microsystems, Germany).
For double-marker immunohistochemistry, the sections underwent two
sequential rounds of single-marker immunostaining. The tissue samples were
incubated ﬁrst with the mouse monoclonal anti-human CD34 clone (1/100
dilution) revealed by the HRP polymer detection kit and AEC substrate
chromogen. After Fc blocking, the sections were then incubated with the rabbit
anti-human C1q (1/500 dilution) revealed by LSABþ System-AP (Dako Code
K0689) and BCIP/NBT substrate chromogen (Dako Cytomation).
Immunoﬂuorescence analysis. Double-marker immunoﬂuorescence stainings
on parafﬁn-embedded human tissues processed as described above for the
immunohistochemical analysis were performed using the following primary
and secondary antibodies: rabbit anti-human C1q 1/500; mouse monoclonal
anti-human multi-cytokeratin (Clone AE1/AE3, 1/100, pH 6, Leica Biosystems
Newcastle Ltd); mouse monoclonal anti-human Vimentin (Ventana, Clone V9, ID
790–2917, ready to use); mouse monoclonal anti-human anti-melanosoma (Ven-
tana, Clone HMB45, ID 790–4336, ready to use); mouse monoclonal anti-human
CD45 (LCA) (Ventana, Clone RP2/18, ID 760-2505, ready to use). After Fc
blocking, bound antibodies were revealed by the following ﬂuorochrome-
conjugated secondary antibodies: Alexa Fluor 568 conjugated goat anti-Rabbit IgG
(Hþ L) (Catalogue number A11011 1/300 dilution) and Alexa Fluor 488-
conjugated goat anti-mouse IgG (Hþ L) (Catalogue number A11001,
1/350 dilution) both from Invitrogen Molecular Probes (Carlsbad, CA). The slides
were counterstained with DAPI Nucleic Acid Stain (Invitrogen Molecular Probes,
Catalogue number D1306). All the sections were analysed under a Leica DM2000
optical microscope (Leica Microsystems) and microphotographs were collected
using a Leica DFC320 digital camera (Leica).
Seven-micrometer-thick tissue sections of snap-frozen tumour masses from WT
and C1qa / mice at the indicated time points, embedded in OCT medium
(Diagnostic Division; Miles Inc), were stained for immunoﬂuorescence analysis
with the following primary antibodies: rat monoclonal anti-mouse C1q (clone 7H8;
HyCult, 1/50 dilution) and rabbit polyclonal anti-mouse C1q (kindly provided
by Prof M. Daha, Leiden, The Netherlands, 1/200 dilution); rat monoclonal
anti-mouse C4 (HyCult, clone 16D2, 1/50 dilution), FITC-conjugated F(ab0)2
fragment goat anti-mouse C3 (Cappel, Catalogue number 55510, 1/500 dilution),
rat monoclonal anti-mouse C3b/iC3b/C3c (Hycult, clone 2/11, 1/50 dilution).
Rabbit antibody to human von Willebrand Factor (vWF) cross-reacting with
the murine counterpart (Dako, code number A0082; 1/400 dilution) and rat
monoclonal anti-mouse CD68 (AbD Serotec, clone FA-11, 1/200 dilution) were
used for double-staining analysis. In some cases, the sections were double stained
with rabbit anti-mouse C1q (1/200 dilution) and goat anti-mouse C3 (1/500
dilution) antibodies) or with goat anti-mouse C3 and rat anti-mouse C3b/iC3b/C3c
(1/50 dilution) antibodies. After Fc blocking, bound antibodies were revealed by
the following ﬂuorochrome-conjugated secondary antibodies: Cy3-coniugated
F(ab’)2 fragment goat anti-rabbit IgG (Catalogue number 111-166-045, 1/200
dilution) and Alexa Fluor 488 goat anti-rat IgG (Catalogue number 112-545-167,
1/200 dilution) both from Jackson ImmunoResearch. The sections were incubated
with DAPI (Sigma-Aldrich, Catalogue D 9542, 1/1,000 dilution) to counterstain
cell nuclei. The slides were mounted with the Mowiol-based antifading medium
(Sigma-Aldrich, Catalogue number 9002-89-5) and analysed in a blinded manners.
Images were acquired with ﬂuorescence microscope Leica DM2000 equipped with
Leica DFC420 camera.
Confocal analysis. B16/F10 cells (3 105) were plated at 37 C on eight-chamber
culture slides (BD Biosciences) coated with C1q (20 mgml 1), FN (20 mgml 1),
FNþC1q (20 mgml 1 each) or poly-lysine (PolyLys; 70 mgml 1) and left to
adhere for 30min. The cells were ﬁxed and permeabilized with the FIX & PERM
Cell Permeabilization Kit (Societa` Italiana Chimici, Italy), stained with N-(7-
nitrobenz-2-oxa-1,3-diazol-4-y)-conjugated phallacidin (NBD-phallacidin)
(Molecular Probes, Invitrogen 1:50 dilution) and mouse monoclonal anti-paxillin
(Merck-Millipore, clone 5H11, 1:100 dilution) followed by Cy3-conjugated F(ab0)2
goat anti-mouse IgG (Jackson ImmunoResearch Catalogue number 115-166-062,
1:300 dilution) as previously described39,66. Images were acquired with the Leica
TCS SP2 confocal system (Leica Microsystems) using the Leica Confocal Software
and a 633 ﬂuorescence objective on a Leica DM IRE2 microscope (Leica
Microsystems) or with a Nikon C1Si confocal system, using the Nikon EZ-C1
Confocal Software and a 633 ﬂuorescence objective on a Nikon TE2000-U inverted
microscope (Nikon, Melville, NY).
Evaluation of angiogenesis and metastases. The microvascular density was
evaluated on CD31-immunostained sections from mouse tumour samples by
counting the number of vessels out of 10 microscopic ﬁelds at  200 magniﬁcation
and averaging the counts. The number of lung parenchymal metastases was
evaluated on haematoxylin and eosin-stained sections and the overall metastatic
burden was assessed as the sum of the areas of the metastatic foci in the evaluated
sections. Measurements were performed using a Leica DMD108 digital microscope.
The analyses were carried out in a blinded manner.
Flow cytometry. Single cell suspensions were stained using standard protocols in
the presence of a saturating concentration of anti-mouse CD16/CD32 (2.4G2)
mAb. The following antibodies were used: anti-CD4 (clone RM4-5, 1:100 dilution),
anti-CD8a (clone53-6.7, 1:100 dilution), anti-CD11b (clone M1/70, 1:200 dilution),
anti-CD25 (clone eBio7D4, 1:100 dilution), anti-CD44 (clone IMF, 1:200 dilution),
anti-CD45 (clone 30-F11, 1:200 dilution), anti-CD62L (clone MEL-14, 1:100
dilution), anti-CD69 (clone H1.2F3, 1:100 dilution), anti-Foxp3 (clone FJK-16 s,
1:100 dilution) and Gr1 (clone RB6-8C5, 1:100 dilution). For intracellular staining,
cells were re-stimulated with 10 ngml 1 of Phorbol 12-Myristate 13-Acetate
(PMA) (Sigma) and 250 ngml 1 of Ionomycin (Calbiochem) in the presence
of GolgiStop (BD Pharmingen) for 4 h. Cells were then permeabilized with
Cytoﬁx/Cytoperm (BD Biosciences) before being stained for Granzyme B
(clone NGZM, 1:100 dilution), IFN-g (clone R4-6A2, 1:100 dilution) and IL-2
(clone ES6-5H4, 1:100 dilution). Antibodies were all purchased from eBioscience
(Life Technologies). Data were acquired using a FACSVerse (Becton Dickinson,
Mountain View, CA) and analysed using FlowJo software, version 7.6 (TreeStar,
Ashland, OR).
Adhesion assay. The adhesion assay was performed as previously reported39.
Brieﬂy, 1 105 B16/F10 cells per 100ml RPMI 1640 (Life technologies) containing
0.1% (v/v) BSA (Sigma-Aldrich, Catalogue number A 2058), labelled with the
ﬂuorescent dye FAST DiI (1:100 dilution), were added to a 96-well plate (Iwaki,
Bibby Scientiﬁc Italia, Italy) for 35min at 37 C in an air/CO2 incubator. The wells
were coated with BSA, C1q (Sigma-Aldrich Catalogue number C1740), and FN
(Roche Life Science, Catalogue number 11051407001) used at the concentration of
20 mgml 1 in pH49 sodium bicarbonate-buffered medium (100mM). PolyLys
(Sigma-Aldrich, Catalogue number P7280) was used as a negative control. After
incubation, the unbound cells were removed and the number of adherent cells was
counted with Inﬁnite200 (absorbance 544 nm, emission 590 nm) (TECAN Italia,
Italy) and referred to a calibration curve established with an increasing number of
labelled cells.
Cell proliferation. B16/F10 cells were serum-starved for 24 h, suspended in
serum-free medium containing 0.1% BSA and seeded in 24 well plates (Corning) at
3 105 cells per well. Prior to cell seeding, the wells were coated with PolyLys
(70 mgml 1), C1q, FN or C1q and FN together as described above. After 18 h,
the supernatant was removed, the cells were lysed with ZAP-OGLOBIN II Lytic
Reagent (Beckman Coulter) and counted with Coulter Particle Counter Z1
(Beckman Coulter). In vivo proliferation studies were performed by injecting 2mg
of BrdU (5-bromo-20-deoxyuridine; eBioscience) i.p. 4 days after the intramuscular
injection of B16/F10 (2 106) cells. Mice were killed 3 h after the BrdU
administration. Tumour cells were harvested and stained for BrdU incorporation
according to manufacturer’s instructions (BrdU Staining Kit for Flow Cytometry
FITC, eBioscience). Tumour cells from non-BrdU-injected mice were used as
negative controls for gating the BrdUþ cells.
Apoptosis. Serum-starved B16/F10 were suspended in serum-free medium
containing 0.1% BSA and seeded at 2 104 cells per well on plates pre-coated with
PolyLys, C1q, FN and the mixture of C1q and FN as reported above. The cells were
left to adhere for 1 h at 37 C and subsequently incubated with 500mM H2O2 for
6 h followed by the addition of 5 mM of CellEvent Caspase-3/7 Green Detection
Reagent (Life Technologies), a ﬂuorogenic substrate for activated caspases 3 and 7.
The reagent consists of a non-ﬂuorescent four amino acid peptide (DEVD)
conjugated to a nucleic acid-binding dye. After activation of caspase-3 or caspase-7
in apoptotic cells, the DEVD peptide is cleaved, enabling the dye to bind to DNA
and to produce a bright ﬂuorogenic response with an absorption/emission maxima
of B502/530 nm. The ﬂuorescence data were acquired with TECAN Inﬁnite200.
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Migration assay. The migration assay was performed as previously reported39
using FAST DiI-labelled (1:100 dilution). B16/F10 cells (2 105 cells) were
resuspended in RPMI 1640 with 0.1% (v/v) BSA and added to the upper chamber
of a transwell system. The cells were allowed to migrate through HTS FluoroBlok
systems with polycarbonate membranes of 8-mm pore size (Becton Dickinson,
Falcon, Italy) coated on the upper side with BSA, C1q and FN used at the
concentration of 20 mgml 1 in pH49 sodium bicarbonate-buffered medium
(100mM). Double-coated wells were prepared as described above. After 18 h, the
number of cells migrated to the lower side of the insert was evaluated as outlined
above for the adherent cells.
ROS and RNS. Tumour-inﬁltrating leucocytes were resuspended in DMEM
and incubated with 2 mM of oxidation-sensitive dye H2DCFDA (20-70-dichloro
dihydroﬂuorescein diacetate; Molecular Probes) at 37 C for 15min. Cells were
then washed with PBS and stained with antibodies against CD45, CD11b and Gr1.
The ﬂuorescent intensity of DCF, that correlates with reactive oxygen species
(ROS) and reactive nitrogen species (RNS) production, within the MDSCs
(CD45þCD11bþGr1þ population) was measured by ﬂow cytometry according to
manufacturer’s instructions (Molecular Probes). The amount of ROS and RNS was
expressed as median ﬂuorescence intensity of the gated populations.
MDSC-mediated T-cell suppression assay. MDSCs were isolated from
tumours from WT and C1qa / mice using Gr1 microbeads (Miltenyi Biotec).
Lymph node cells (1 105) from naı¨ve C1qa / mice were labelled with CFSE
(5-(and-6)-carboxyﬂuorescein succinimidyl ester; Molecular Probes) and
stimulated with CD3/CD28 dynabeads (Invitrogen) at 1:1 ratio (beads/cells) in the
presence or absence of WT or C1qa / MDSCs (5 104). T-cell proliferation was
assessed by ﬂow cytometry measuring the CFSE dilution after 3 days of co-culture.
Unstimulated CFSE-labelled lymphocytes were used as basal proliferation control.
Statistical analysis. Data from in vivo mouse models were analysed using
two-way analysis of variance (ANOVA), Tukey–Kramer test, and in vitro
experiments with unpaired two-tailed Student t-test or one-way ANOVA with
Bonferroni corrections. Results were expressed as mean±s.e.m. Non-parametric
data were assessed by Mann–Whitney U-tests and the results were expressed as
median and interquartile range. P values of o0.05 were considered signiﬁcant.
All statistical analyses were performed using Prism 6 software (GraphPad Software
Inc, La Jolla, CA).
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